Transforming cancer care through AI-native clinical infrastructure
image credit- shutterstock
Australian startup Lumonus, a leader in artificial intelligence (AI) powered radiation oncology workflow solutions, has announced the close of its A$25 million Series B financing round. The round was led by Aviron Investment Management with continued participation from Oncology Ventures.
This funding highlights the strong clinical adoption of Lumonus AI, with leading health systems across the United States, Australia, and Europe who are already integrating the platform into routine clinical care. To date, the Lumonus AI platform has supported clinicians in consulting and prescribing over 280,000 cancer treatments and has automated the creation of over 75,000 cancer treatment plans, demonstrating its impact in streamlining critical oncology workflows and improving the efficiency and consistency of care.
Lumonus' leadership team brings more than 100 years of combined clinical, operational, and technical experience from cancer centers across the United States, Europe, and APAC. This deep, hands-on expertise grounds the company in the realities of oncology care and drives its mission to deliver solutions that empower care teams to provide high-quality, efficient treatment.
More specifically, the Series B funding will be used to expand US go-to-market and clinical success teams, advance its flagship products, Lumonus AI Physician and Lumonus AI Dosimetry, and invest in clinical informatics capabilities. The company will also expand its work with health systems to harness real-world evidence, measure quality, improve operational performance, and deliver more personalised, data-driven care.
